Innogen’s Newly Approved GLP-1 Contender Girds For China Ozempic Battle

 
• By Dexter Jie Yan

Innogen is hoping the approval of its once-weekly GLP-1 drug Diabegone will allow it to chip away at Ozempic’s dominance in the Chinese diabetes market.

insulin injection
Innogen's Diabegone is a newly approved homegrown contender to Novo Nordisk's Ozempic in China's domestic market. • Source: Shutterstock

More from China

More from Business